Choice and use of antifungal drugs;Choix et emploi des médicaments antifongiques

Revue du Praticien

Volumn 51, Issue 7, 2001, Pages 752-757

  Dupont, B ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CYCLODEXTRIN; DRUG CARRIER; PHOSPHOLIPID TRANSFER PROTEIN; TRIAZOLE DERIVATIVE;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG INDICATION; DRUG SAFETY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; MYCOSIS; PRACTICE GUIDELINE;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; FLUCONAZOLE; FLUCYTOSINE; HUMANS; ITRACONAZOLE; LUNG DISEASES, FUNGAL; MYCOSES; TIME FACTORS;

EID: 17144437596     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Established and emerging invasive mycoses
2. The new fungal opportunists are coming
3. The impact of changing epidemiology of fungal infections in the 1990s
4. Endemic mycoses in AIDS: A clinical review
5. Epidemiology of nosocomial fungal infections
6. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System
7. Mycoses viscérales émergentes Scedosporium Fusarium Trichosporon
8. Carrier effects on biological activity of Amphotericin B
9. A randomized, double-bind comparative trial evaluating the safety of liposomal Amphotericin B versus Amphotericin B lipid complex in the empirical treatment of febrile neutropenia
10. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases
11. Overview of the lipid formulations of Amphotericin B
12. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases
13. Clinical significance of nephrotoxicity in patients treated with amphotericin B
14. Amphotericin B in children with malignant disease: A comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion
15. Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients
16. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia
17. Practice guidelines for the treatment of Candidiasis
18. International conference for the development of a consensus on the management and the prevention of severe candidal infections
19. Practice guidelines for the management of cryptococcal disease
20. Comparison of amphotericin B and fluconazole efficacy in the treatment of cryptococcosis in HIV-negative patients: Retrospective analysis of 83 cases
21. NIAID Mycoses study group: Multicenter trial of oral itraconazole therapy for invasive aspergillosis
22. Traitement des histoplasmoses et de la coccidioïdomycose
23. Ancotil: The past, present and future of antimycotic combination therapy
24. Candidoses viscérales
25. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole
26. Antifungal activity of a new triazole, voriconazole (UK-109-496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi
27. New drugs and novel targets for treatment of invasive fungal infections in patients with cancer
28. Comparison of in vitro activities of the new triazole posaconazole and the echinocandins MK 0991 (L-743, 872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
29. In vitro activity of a new oral triazole, BMS-207147 (ER-30346)
30. In vitro preclininical evaluation studies with the echinocandin antifungal MK 0991 (L-743-872)
31. In vitro activity of a new pneumocandin antifungal, L-743-872 against azole-susceptible and -resistant Candida species
32. Sordarins: A new class of antifungals with inhibition of the protein synthesis elongation cycle in yeasts
33. Pradimicins: A novel class or broad-spectrum antifungal compounds
34. Practice guidelines for diseases caused by Aspergillus
35. Cryptococcose